GBNHF vs. ACON, BACK, UPHL, BTTX, AVHIW, AVHIU, ACONW, AONC, DHACW, and LFMDP
Should you be buying Greenbrook TMS stock or one of its competitors? The main competitors of Greenbrook TMS include Aclarion (ACON), IMAC (BACK), UpHealth (UPHL), Better Therapeutics (BTTX), Achari Ventures Holdings Corp. I (AVHIW), Achari Ventures Holdings Corp. I (AVHIU), Aclarion (ACONW), American Oncology Network (AONC), Digital Health Acquisition (DHACW), and LifeMD (LFMDP). These companies are all part of the "healthcare" industry.
Greenbrook TMS vs.
Greenbrook TMS (NASDAQ:GBNHF) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.
Greenbrook TMS has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.
Aclarion received 3 more outperform votes than Greenbrook TMS when rated by MarketBeat users.
Greenbrook TMS has a net margin of -73.08% compared to Aclarion's net margin of -10,967.15%. Greenbrook TMS's return on equity of 0.00% beat Aclarion's return on equity.
In the previous week, Aclarion had 1 more articles in the media than Greenbrook TMS. MarketBeat recorded 1 mentions for Aclarion and 0 mentions for Greenbrook TMS. Aclarion's average media sentiment score of 0.14 beat Greenbrook TMS's score of 0.00 indicating that Aclarion is being referred to more favorably in the news media.
Aclarion has a consensus price target of $1.50, suggesting a potential upside of 710.37%. Given Aclarion's higher possible upside, analysts clearly believe Aclarion is more favorable than Greenbrook TMS.
7.5% of Aclarion shares are held by institutional investors. 21.7% of Greenbrook TMS shares are held by insiders. Comparatively, 1.7% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Aclarion has lower revenue, but higher earnings than Greenbrook TMS.
Summary
Aclarion beats Greenbrook TMS on 8 of the 14 factors compared between the two stocks.
Get Greenbrook TMS News Delivered to You Automatically
Sign up to receive the latest news and ratings for GBNHF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GBNHF vs. The Competition
Greenbrook TMS Competitors List
Related Companies and Tools
This page (NASDAQ:GBNHF) was last updated on 11/2/2024 by MarketBeat.com Staff
Free GBNHF Stock Alerts